Kalaris Therapeutics (KLRS) Accumulated Expenses (2019 - 2026)
Kalaris Therapeutics (KLRS) reported Accumulated Expenses of $7.27 million for Q2 2026, up 83.0% from $3.97 million a year earlier and up 6.0% from the prior quarter.
Powered by 
Analysis
Kalaris Therapeutics (KLRS) Accumulated Expenses (2019 - 2026) Analysis & Trends
At the end of FY2025, Kalaris Therapeutics posted Accumulated Expenses of $8.12 million, up 269.8% from FY2024.
- Accumulated Expenses has a five-year compound annual growth rate of 1.5% (FY2020 to FY2025).
- By year, Accumulated Expenses came in at $2.2 million in FY2024 (-78.2%), $10.09 million in FY2023 (-27.9%), $13.99 million in FY2022 (-30.6%) and $20.15 million in FY2021 (+167.6%).
- Five-year quarterly Accumulated Expenses spans a low of $1.36 million in Q3 2024 and a high of $20.15 million in Q4 2021.
- Year over year, Accumulated Expenses has now increased in each of the last five quarters, with growth averaging 93.0% over the last eight quarters.
- The high point for year-over-year Accumulated Expenses in five years was Q3 2025 (growth of 281.7%); the low point was Q3 2024 (a decline of 91.5%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $6.86 million (Q1 2026), $8.12 million (Q4 2025) and $5.2 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Kalaris Therapeutics | 68.80 Mn | 68.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.27 Mn |
| Mar 31, 2026 | 6.86 Mn |
| Dec 31, 2025 | 8.12 Mn |
| Sep 30, 2025 | 5.20 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Mar 31, 2024 | 4.60 Mn |
| Dec 31, 2023 | 10.09 Mn |
| Sep 30, 2023 | 15.92 Mn |
| Jun 30, 2023 | 16.73 Mn |
| Mar 31, 2023 | 12.29 Mn |
| Dec 31, 2022 | 13.99 Mn |
| Sep 30, 2022 | 13.68 Mn |
| Jun 30, 2022 | 13.12 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 20.15 Mn |
| Sep 30, 2021 | 15.80 Mn |
API Access
Kalaris Therapeutics Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=KLRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "KLRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=KLRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();